Comparing Aspirin and Rivaroxaban to Prevent Blood Clots in Myeloma Patients
Compares aspirin and rivaroxaban to prevent blood clots in adults with multiple myeloma.
Plain-language title generated from the registry record
Registry title: Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma
Key facts
- Where
- Wuhan, ChinaSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT06580223, who can take part
Where in China
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Trial code
- NCT06580223
- Record updated
- 18 July 2025
- Original description
The aim of this study is to evaluate the efficacy and safety of aspirin and rivaroxaban in thromboprophylaxis in Chinese MM patients at high risk for MM-associated VTE.Read full original descriptionShow less
Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma: A Prospective, Multicenter, Open-Label, Randomized Trial
The aim of this study is to evaluate the efficacy and safety of aspirin and rivaroxaban in thromboprophylaxis in Chinese MM patients at high risk for MM-associated VTE.
Inclusion: Newly diagnosed multiple myeloma (according to Guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)); High risk of VTE (according to Expert consensus on the prevention and treatment of multiple myeloma related venous thromboembolism in China (2022)); Life expectancy exceeding 12 months; Gender: not specified, Age: 18-90 years; Serum HIV antigen or antibody negative; HCV antibody negative, or HCV antibody positive with HCV RNA negative; Echocardiogram shows a left ventricular ejection fraction of ≥50%; Ability to sign an informed consent form.
Exclusion: Active bleeding; Patients already on antiplatelet therapy for other cardiovascular or cerebrovascular diseases; When initiating treatment, platelet count below 50 G/L, or with PT prolonged by more than 3 seconds, and APTT prolonged by more than 10 seconds; Abnormal liver function (ALT or AST greater than 3 times the upper limit of normal, or total bilirubin greater than 2 times the upper limit of normal); Abnormal renal function (creatinine clearance < 30 mL/min); Pregnant women or women who are breastfeeding; Active gastrointestinal ulceration; Unable to cooperate in completing the clinical trial; Already enrolled in other clinical studies; Diagnosed with smoldering multiple myeloma or plasma cell leukemia.